U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C29H32N4.CH4O3S
Molecular Weight 532.697
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LIFARIZINE METHANESULFONATE

SMILES

CS(O)(=O)=O.CC1=C(CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)N=C(N1)C5=CC=C(C)C=C5

InChI

InChIKey=CGPIUYHUELMXMK-UHFFFAOYSA-N
InChI=1S/C29H32N4.CH4O3S/c1-22-13-15-26(16-14-22)29-30-23(2)27(31-29)21-32-17-19-33(20-18-32)28(24-9-5-3-6-10-24)25-11-7-4-8-12-25;1-5(2,3)4/h3-16,28H,17-21H2,1-2H3,(H,30,31);1H3,(H,2,3,4)

HIDE SMILES / InChI

Molecular Formula C29H32N4
Molecular Weight 436.5912
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula CH4O3S
Molecular Weight 96.106
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Lifarizine is a use- and voltage-dependent antagonist of human voltage sensitive sodium currents. Lifarizine inhibited both the plateau and the spike phases of the Ca2+ increases suggesting that, in addition to its known sodium channel blocking properties, it may also inhibit more than one class of calcium channel in the synaptosomes. Lifarizine reduced both infarct area and volume in the mouse with middle cerebral artery occlusion. Lifarizine was in phase II for the treatment of stroke but this investigation was discontinued.

Approval Year

PubMed

PubMed

TitleDatePubMed
MR evaluation of calcium entry blockers with putative cerebroprotective effects in acute cerebral ischaemia.
1990
Neuroprotective efficacy of lifarizine (RS-87476) in a simplified rat survival model of 2 vessel occlusion.
1995 Dec
Selectivity of the neuroprotective agent lifarizine.
1995 Sep
Efficacy and tolerability of lifarizine in acute ischemic stroke. A pilot study. Lifarizine Study Group.
1995 Sep 15
Inhibition by lifarizine of intracellular Ca2+ rises and glutamate exocytosis in depolarized rat cerebrocortical synaptosomes and cultured neurones.
1996 May
Focal cerebral ischemia in the mouse: hypothermia and rapid screening of drugs.
1998 Feb
Frequency-independent blockade of cardiac Na+ channels by riluzole: comparison with established anticonvulsants and class I anti-arrhythmics.
2000 Mar-Apr
Reasons why stroke trials underestimate the neuroprotective effects of drugs.
2002 Jan
Patents

Patents

Sample Use Guides

Single dose 100 mg/kg
Route of Administration: Other
Substance Class Chemical
Created
by admin
on Sat Dec 16 05:00:22 UTC 2023
Edited
by admin
on Sat Dec 16 05:00:22 UTC 2023
Record UNII
AKZ5B7DOP6
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LIFARIZINE METHANESULFONATE
Common Name English
PIPERAZINE, 1-(DIPHENYLMETHYL)-4-((5-METHYL-2-(4-METHYLPHENYL)-1H-IMIDAZOL-4-YL)METHYL)-, METHANESULFONATE
Systematic Name English
1-((2-(4-METHYLPHENYL)-5-METHYL)-1H-IMIDAZOL-4-YL-METHYL)-4-DIPHENYLMETHYL-PIPERAZINE METHANESULPHONATE
Systematic Name English
Code System Code Type Description
PUBCHEM
131635410
Created by admin on Sat Dec 16 05:00:22 UTC 2023 , Edited by admin on Sat Dec 16 05:00:22 UTC 2023
PRIMARY
FDA UNII
AKZ5B7DOP6
Created by admin on Sat Dec 16 05:00:22 UTC 2023 , Edited by admin on Sat Dec 16 05:00:22 UTC 2023
PRIMARY
CAS
130565-83-2
Created by admin on Sat Dec 16 05:00:22 UTC 2023 , Edited by admin on Sat Dec 16 05:00:22 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE